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Introduction {#jdi12764-sec-0005}
============

Type 2 diabetes mellitus is a progressive disease characterized by insulin deficiency and insulin resistance. Guidelines recommend insulin therapy be initiated when patients with progressive type 2 diabetes mellitus do not achieve or maintain proper glycemic control on oral antihyperglycemic agents alone and add‐on therapies[1](#jdi12764-bib-0001){ref-type="ref"}, [2](#jdi12764-bib-0002){ref-type="ref"}.

Dipeptidyl peptidase‐4 (DPP‐4) inhibitors prevent the degradation of gastrointestinal incretins glucagon‐like peptide‐1 (GLP‐1) and glucose‐dependent insulinotropic polypeptide (GIP), resulting in improved glycemic control by increasing levels of GLP‐1 and GIP[3](#jdi12764-bib-0003){ref-type="ref"}, [4](#jdi12764-bib-0004){ref-type="ref"}, [5](#jdi12764-bib-0005){ref-type="ref"}. The efficacy and safety of DPP‐4 inhibitors and insulin combination therapy have been evaluated in several previous studies, including systematic reviews and meta‐analyses based on findings from randomized controlled trials (RCTs)[6](#jdi12764-bib-0006){ref-type="ref"}, [7](#jdi12764-bib-0007){ref-type="ref"}. However, there are only limited data comparing DPP‐4 inhibitors with other antihyperglycemic agents in combination with insulin, especially head‐to‐head comparisons, and no systemic reviews or meta‐analyses have been published.

Therefore, the aim of the current systematic review and meta‐analysis was to evaluate the efficacy and safety of DPP‐4 inhibitors compared with a placebo or other antihyperglycemic agents in combination with insulin therapy.

Methods {#jdi12764-sec-0006}
=======

Data collection and searching strategy {#jdi12764-sec-0007}
--------------------------------------

Studies were identified by a literature search of MEDLINE^®^ (PubMed), the Cochrane Central Register of Controlled Trials (CENTRAL) and EMBASE^®^ until December 2016. Documents for approved medications were searched for trials at <http://www.clinicalstudyresults.org> and <http://www.clinicaltrials.gov>.

The following terms were searched: type 2 diabetes; DPP‐4 inhibitors (DPP‐4i); metformin (MET); alpha‐glucosidase inhibitors (AGI); thiazolidinediones (TZD); glucagon‐like peptide‐1 receptor agonist (GLP‐1RA); sodium--glucose cotransporter 2 inhibitors (SGLT‐2i); acarbose; miglitol; voglibose; rosiglitazone; pioglitazone; troglitazone; sitagliptin; vildagliptin; saxagliptin; alogliptin; linagliptin; liraglutide; lixisenatide; exenatide; dapagliflozin; canagliflozin; empagliflozin; and RCTs.

Eligibility criteria {#jdi12764-sec-0008}
--------------------

The inclusion criteria were: (i) RCTs comparing the addition of DPP‐4 inhibitors with insulin, with the addition of a placebo or other active hypoglycemic agents to insulin therapy; (ii) study duration ≥12 weeks; (iii) studies carried out in type 2 diabetes patients; and (iv) the efficacy of glucose control was the primary outcome of the study. Non‐RCTs carried out in type 2 diabetes patients, studies in type 1 diabetes patients and studies with duration \<12 weeks were excluded.

Data extraction {#jdi12764-sec-0009}
---------------

Two review authors (GXY and YWJ) independently extracted the following data from each study: publication data (title, first author, year), study design, baseline characteristics of the study population (sample size, age, sex, duration of type 2 diabetes mellitus, body mass index \[BMI\] and glycated hemoglobin \[HbA1c\]), description of the study drugs, treatment duration and primary outcome measures (changes from baseline to study end‐point for HbA1c). Discrepancies were resolved by a third investigator (CL).

Assessment of study quality and risk of bias {#jdi12764-sec-0010}
--------------------------------------------

A visual inspection of the funnel plot and the Egger\'s test of the funnel plot were used to assess the publication bias. The quality of all included studies was assessed by the Cochrane risk of bias tool including selection bias, performance bias, detection bias, attrition bias, reporting bias and others[8](#jdi12764-bib-0008){ref-type="ref"}.

Statistical analysis {#jdi12764-sec-0011}
--------------------

The weighted mean difference (WMD) and 95% confidence interval (CI) were calculated for continuous variables, including the change in HbA1c, fasting plasma glucose (FPG), postprandial plasma glucose (PPG), bodyweight and daily dosage of insulin from baseline. The risk ratio (RR) and 95% confidence interval (CI) were calculated to analyze the risk of hypoglycemia and severe hypoglycemia. The between‐study heterogeneity was distributed as the χ^2^ statistic, and statistical significance was reached when *P* \< 0.05. The Higgins *I* ^2^ statistics were used to quantify the percentage of the total variance in the summary estimate due to between‐study heterogeneity. Fixed effects and random effects models were used with low and high levels of heterogeneity, respectively. Review Manager statistical software package (version 5.3; The Nordic Cochrane Center, Copenhagen, Denmark) was used for statistical analyses. This meta‐analysis was carried out according to the Preferred Reporting Items for Systematic Reviews and Meta‐analyses guidelines.

Results {#jdi12764-sec-0012}
=======

Characteristics of enrolled studies {#jdi12764-sec-0013}
-----------------------------------

Ultimately, 36 studies that met the inclusion criteria were analyzed, including 7 studies that compared a placebo with a combination of a DPP‐4 inhibitor and insulin (DPP4i/INS)[9](#jdi12764-bib-0009){ref-type="ref"}, [10](#jdi12764-bib-0010){ref-type="ref"}, [11](#jdi12764-bib-0011){ref-type="ref"}, [12](#jdi12764-bib-0012){ref-type="ref"}, [13](#jdi12764-bib-0013){ref-type="ref"}, [14](#jdi12764-bib-0014){ref-type="ref"}, [15](#jdi12764-bib-0015){ref-type="ref"}, 3 studies that compared a placebo with a combination of metformin and insulin (MET/INS)[16](#jdi12764-bib-0016){ref-type="ref"}, [17](#jdi12764-bib-0017){ref-type="ref"}, [18](#jdi12764-bib-0018){ref-type="ref"}, 7 studies that compared a placebo with a combination of thiazolidinedionesin and insulin (TZD/INS)[17](#jdi12764-bib-0017){ref-type="ref"}, [19](#jdi12764-bib-0019){ref-type="ref"}, [20](#jdi12764-bib-0020){ref-type="ref"}, [21](#jdi12764-bib-0021){ref-type="ref"}, [22](#jdi12764-bib-0022){ref-type="ref"}, [23](#jdi12764-bib-0023){ref-type="ref"}, [24](#jdi12764-bib-0024){ref-type="ref"}, 5 studies that compared a placebo with a combination of an alpha‐glucosidase inhibitor and insulin (AGI/INS)[25](#jdi12764-bib-0025){ref-type="ref"}, [26](#jdi12764-bib-0026){ref-type="ref"}, [27](#jdi12764-bib-0027){ref-type="ref"}, [28](#jdi12764-bib-0028){ref-type="ref"}, [29](#jdi12764-bib-0029){ref-type="ref"}, 7 studies that compared a placebo with a combination of a GLP‐1 receptor agonist and insulin (GLP‐1RA/INS)[30](#jdi12764-bib-0030){ref-type="ref"}, [31](#jdi12764-bib-0031){ref-type="ref"}, [32](#jdi12764-bib-0032){ref-type="ref"}, [33](#jdi12764-bib-0033){ref-type="ref"}, [34](#jdi12764-bib-0034){ref-type="ref"}, [35](#jdi12764-bib-0035){ref-type="ref"}, [36](#jdi12764-bib-0036){ref-type="ref"} and 8 studies that compared a placebo with a combination of SGLT‐2i and insulin (SGLT‐2i/INS)[37](#jdi12764-bib-0037){ref-type="ref"}, [38](#jdi12764-bib-0038){ref-type="ref"}, [39](#jdi12764-bib-0039){ref-type="ref"}, [40](#jdi12764-bib-0040){ref-type="ref"}, [41](#jdi12764-bib-0041){ref-type="ref"}, [42](#jdi12764-bib-0042){ref-type="ref"}, [43](#jdi12764-bib-0043){ref-type="ref"}, [44](#jdi12764-bib-0044){ref-type="ref"}. Details are presented in a flow chart (Figure [1](#jdi12764-fig-0001){ref-type="fig"}). Characteristics of the included studies are outlined in Table [S1](#jdi12764-sup-0002){ref-type="supplementary-material"}. Figure [S1](#jdi12764-sup-0001){ref-type="supplementary-material"} summarizes the risks of bias of the included studies.

![Flow chart of included studies.](JDI-9-813-g001){#jdi12764-fig-0001}

Methodological quality {#jdi12764-sec-0014}
----------------------

All the included studies were randomized, placebo‐controlled trials. Most studies reported age, sex, diabetes duration, HbA1c, BMI, bodyweight between the comparison groups at baseline. Overall, the risk of bias was low. Figure [S1](#jdi12764-sup-0001){ref-type="supplementary-material"} summarizes the risks of bias of the included studies. Funnel plots assessing the precision of the data suggested a low risk of publication bias (data not shown).

Efficacy outcomes {#jdi12764-sec-0015}
-----------------

### Changes in HbA1c {#jdi12764-sec-0016}

The HbA1c‐lowering efficacy was significantly greater with DPP‐4i/INS than with PBO/INS (WMD −0.53%, 95% CI: −0.63, −0.43, *P* \< 0.01; Figure [2](#jdi12764-fig-0002){ref-type="fig"}; Table [1](#jdi12764-tbl-0001){ref-type="table"}). The placebo‐corrected HbA~1c~ change from baseline was greater with MET/INS than with DPP‐4i/INS (*P* \< 0.05). There was no significant difference in the placebo‐corrected HbA1c change from baseline between DPP‐4i/INS and AGI/INS, TZD/INS, GLP‐1RA/INS and SGLT‐2i/INS (*P* \> 0.05).

![Change from baseline in glycated hemoglobin (HbA1c) of dipeptidyl peptidase‐4 (DPP‐4) inhibitor/insulin treatment. CI, confidence interval; PBO, placebo.](JDI-9-813-g002){#jdi12764-fig-0002}

###### 

Comparisons of glycated hemoglobin change from baseline in different treatment groups

                                   No. studies   No. participants (active agents vs PBO)   WMD from baseline   95% CI         *P*‐value
  -------------------------------- ------------- ----------------------------------------- ------------------- -------------- -----------------------------------------------
  HbA1c change from baseline (%)                                                                                              
  DPP‐4i/INS                       7             1,848/1,692                               −0.53               −0.63, −0.43   \<0.01[a](#jdi12764-note-0001){ref-type="fn"}
  MET/INS                          3             127/135                                   −0.88               −1.11, −0.64   \<0.01[a](#jdi12764-note-0001){ref-type="fn"}
  AGI/INS                          5             375/367                                   −0.55               −1.12, 0.01    0.06
  TZD/INS                          7             758/760                                   −0.61               −0.80, −0.41   \<0.01[a](#jdi12764-note-0001){ref-type="fn"}
  SGLT‐2i/INS                      8             1,658/1,585                               −0.66               −0.79, −0.53   \<0.01[a](#jdi12764-note-0001){ref-type="fn"}
  GLP‐1RA/INS                      7             1,393/1,223                               −0.74               −1.07, −0.41   \<0.01[a](#jdi12764-note-0001){ref-type="fn"}

*P*‐value \< 0.05. AGI, alpha‐glucosidase inhibitors; CI, confidence interval; DPP‐4i, dipeptidyl peptidase‐4 inhibitor; GLP‐1RA, glucagon‐like peptide‐1 receptor agonist; HbA1c, glycated hemoglobin; INS, insulin; MET, metformin; PBO, placebo; TZD, thiazolidinediones; SGLT‐2i, sodium--glucose cotransporter 2 inhibitor; WMD, weighted mean difference.

John Wiley & Sons, Ltd

### Changes in FPG {#jdi12764-sec-0017}

When DPP4i/INS treatment was compared with PBO/INS treatment, the change in FPG was not significant (WMD −0.32 mmol/L, 95% CI: −0.75, 0.11, *P* = 0.14; *I* ^2^ = 100%, random effects model was used; Table [2](#jdi12764-tbl-0002){ref-type="table"}). The difference in the placebo‐corrected FPG change from baseline between DPP‐4i/INS and MET/INS, AGI/INS, TZD/INS, GLP‐1RA/INS and SGLT‐2i/INS treatments was not significant (*P* \> 0.05).

###### 

Comparisons of fasting plasma glucose change from baseline in different treatment groups

                                      No. studies   No. participants (active agents vs PBO)   WMD from baseline   95% CI         *P*‐value
  ----------------------------------- ------------- ----------------------------------------- ------------------- -------------- -----------------------------------------------
  FPG change from baseline (mmol/L)                                                                                              
  DPP‐4i/INS                          7             1,848/1,692                               −0.32               −0.75, 0.11    0.14
  MET/INS                             3             127/135                                   −0.72               −1.58, 0.14    0.10
  AGI/INS                             4             268/267                                   −0.02               −0.30, 0.26    0.87
  TZD/INS                             6             750/750                                   −1.16               −3.15, 0.83    0.25
  SGLT‐2i/INS                         6             800/753                                   −0.63               −1.39, 0.13    0.10
  GLP‐1RA/INS                         7             1,393/1,223                               −0.46               −0.87, ‐0.05   \<0.05[a](#jdi12764-note-0002){ref-type="fn"}

*P*‐value \< 0.05. AGI, alpha‐glucosidase inhibitors; CI, confidence interval; DPP‐4i, dipeptidyl peptidase‐4 inhibitor; FPG, fasting plasma glucose; GLP‐1RA, glucagon‐like peptide‐1 receptor agonist; HbA1c, glycated hemoglobin; INS, insulin; MET, metformin; PBO, placebo; SGLT‐2i, sodium--glucose cotransporter 2 inhibitor; SU, sulfonylurea; TZD, thiazolidinediones; WMD, weighted mean difference.

John Wiley & Sons, Ltd

### Changes in PPG {#jdi12764-sec-0018}

The PPG‐lowering efficacy was significantly greater with DPP‐4i/INS than with PBO/INS (WMD −1.65 mmol/L, 95% CI: −2.34, −0.96, *P* \< 0.01; *I* ^2^ = 100%, random effects model was used; Table [3](#jdi12764-tbl-0003){ref-type="table"}). The placebo‐corrected PPG change from baseline was greater with SGLT‐2i/INS than with DPP‐4i/INS (*P* \< 0.05). The placebo‐corrected PPG change from baseline between DPP‐4i/INS and AGI/INS and GLP‐1RA/INS treatments was not significantly different (*P* \> 0.05).

###### 

Comparisons of postprandial plasma glucose change from baseline in different treatment groups

                                      No. studies   No. participants (active agents vs PBO)   WMD from baseline   95% CI         *P*‐value
  ----------------------------------- ------------- ----------------------------------------- ------------------- -------------- -----------
  PPG change from baseline (mmol/L)                                                                                              
  DPP‐4i/INS                          2             626/470                                   −1.65               −2.34, −0.96   \<0.01
  AGI/INS                             3             208/207                                   −1.76               −4.19, 0.66    0.15
  GLP‐1RA/INS                         3             705/547                                   −2.87               −8.98, 3.23    0.36
  SGLT‐2i/INS                         2             146/83                                    −2.62               −2.86, −2.37   \<0.01

AGI, alpha‐glucosidase inhibitors; CI, confidence interval; DPP‐4i, dipeptidyl peptidase‐4 inhibitor; GLP‐1RA, glucagon‐like peptide‐1 receptor agonist; HbA1c, glycated hemoglobin; INS, insulin; PBO, placebo; PPG, postprandial plasma glucose; SGLT‐2i, sodium--glucose cotransporter 2 inhibitor; WMD, weighted mean difference.

John Wiley & Sons, Ltd

### Changes in bodyweight {#jdi12764-sec-0019}

When DPP4i/INS treatment was compared with PBO/INS treatment, the change in bodyweight was not significant (WMD 0.18 kg, 95% CI: −0.08, 0.44, *P* = 0.17; Table [4](#jdi12764-tbl-0004){ref-type="table"}). When placebo‐corrected, bodyweight was significantly decreased with SGLT‐2i/INS and GLP‐1RA/INS compared with DPP‐4i/INS (*P* \< 0.05), and was significantly increased with TZD/INS compared with DPP‐4i/INS (*P* \< 0.05). There was no significant difference in placebo‐corrected bodyweight change from baseline between DPP‐4i/INS and AGI/INS treatments (*P* \> 0.05).

###### 

Comparisons of bodyweight change from baseline in different treatment groups

                                         No. studies   No. participants (active agents vs PBO)   WMD from baseline   95% CI         *P*‐value
  -------------------------------------- ------------- ----------------------------------------- ------------------- -------------- -----------------------------------------------
  Bodyweight change from baseline (kg)                                                                                              
  DPP‐4i/INS                             7             1,848/1,692                               0.18                −0.08, 0.44    0.17
  MET/INS                                3             127/135                                   −2.66               −3.91, −1.41   \<0.01[a](#jdi12764-note-0004){ref-type="fn"}
  AGI/INS                                4             268/267                                   −0.70               −2.15, 0.75    0.34
  TZD/INS                                6             655/656                                   1.88                0.29, 3.46     0.02[a](#jdi12764-note-0004){ref-type="fn"}
  SGLT‐2i/INS                            7             994/946                                   −1.89               −2.31, −1.48   \<0.01[a](#jdi12764-note-0004){ref-type="fn"}
  GLP‐1RA/INS                            7             1,393/1,223                               −1.70               −2.53, −0.88   \<0.01[a](#jdi12764-note-0004){ref-type="fn"}

*P*‐value \< 0.05. AGI, alpha‐glucosidase inhibitors; CI, confidence interval; DPP‐4i, dipeptidyl peptidase‐4 inhibitor; GLP‐1RA, glucagon‐like peptide‐1 receptor agonist; HbA1c, glycated hemoglobin; INS, insulin; MET, metformin; PBO, placebo; SGLT‐2i, sodium--glucose cotransporter 2 inhibitor; TZD, thiazolidinediones; WMD, weighted mean difference.

John Wiley & Sons, Ltd

### Changes in the dosage of insulin use {#jdi12764-sec-0020}

The change in daily insulin doses was significantly greater with DPP‐4i/INS than with PBO/INS (WMD −2.17 units/day, 95% CI: −3.18, −1.15, *P* \< 0.01; *I* ^2^ = 99%, random effects model was used; Table [5](#jdi12764-tbl-0005){ref-type="table"}). The placebo‐corrected daily insulin dosage was significantly decreased with TZD/INS compared with DPP‐4i/INS (*P* \< 0.05). Comparisons of the placebo‐corrected insulin dosage change from baseline between DPP‐4i/INS and AGI/INS, GLP‐1RA/INS and SGLT‐2i/INS treatments showed that the difference was not significant (*P* \> 0.05).

###### 

Comparisons of daily insulin dosage change from baseline in different treatment groups

                                                      No. studies   No. participants (active agents vs PBO)   WMD from baseline   95% CI          *P*‐value
  --------------------------------------------------- ------------- ----------------------------------------- ------------------- --------------- -----------------------------------------------
  Daily insulin dosage change from baseline (U/day)                                                                                               
  DPP‐4i/INS                                          4             1,307/1,154                               −2.17               −3.18, −1.15    \<0.01[a](#jdi12764-note-0005){ref-type="fn"}
  AGI/INS                                             2             142/141                                   0.28                −2.85, 3.40     0.86
  TZD/INS                                             5             518/524                                   −16.15              −25.89, −6.42   \<0.01[a](#jdi12764-note-0005){ref-type="fn"}
  SGLT‐2i/INS                                         3             545/490                                   −6.00               −12.28, 0.27    0.06
  GLP‐1RA/INS                                         7             1,393/1,223                               −3.39               −4.74, −2.04    \<0.01[a](#jdi12764-note-0005){ref-type="fn"}

*P*‐value \< 0.05. AGI, alpha‐glucosidase inhibitors; CI, confidence interval; DPP‐4i, dipeptidyl peptidase‐4 inhibitor; GLP‐1RA, glucagon‐like peptide‐1 receptor agonist; HbA1c, glycated hemoglobin; INS, insulin; PBO, placebo; SGLT‐2i, sodium--glucose cotransporter 2 inhibitor; TZD, thiazolidinediones; U, unit; WMD, weighted mean difference.

John Wiley & Sons, Ltd

Safety outcomes {#jdi12764-sec-0021}
---------------

In the subgroup analysis of safety outcomes, we analyzed the incidence of hypoglycemia and severe hypoglycemia. The risk of hypoglycemia or severe hypoglycemia between treatment with DPP4i/INS and PBO/INS was similar (*I* ^2^ = 48% for the incidence of hypoglycemia, *I* ^2^ = 41% for the incidence of severe hypoglycemia, fixed effects model was used). In the AGI/INS treatment group, the risk of hypoglycemia significantly increased compared with the PBO/INS treatment group (RR 1.39, 95% CI: 1.07, 1.81, *P* = 0.01). There was no significant difference in the risk of hypoglycemia or severe hypoglycemia in the other treatment groups compared with the PBO/INS group (Table [6](#jdi12764-tbl-0006){ref-type="table"}). The placebo‐corrected risk of hypoglycemia or severe hypoglycemia between DPP‐4i/INS and MET/INS, TZD/INS, GLP‐1RA/INS and SGLT‐2i/INS treatments showed no significant difference (*P* \> 0.05).

###### 

Comparisons of hypoglycemia or severe hypoglycemia risk in different treatment groups

                                         No. studies   No. participants (active agents vs PBO)   WMD from baseline   95% CI       *P*‐value
  -------------------------------------- ------------- ----------------------------------------- ------------------- ------------ ---------------------------------------------
  Incidence of hypoglycemia (%)                                                                                                   
  DPP‐4i/INS                             7             1,848/1,692                               1.02                0.91, 1.16   0.71
  MET/INS                                3             127/135                                   0.96                0.82, 1.12   0.59
  AGI/INS                                5             375/367                                   1.39                1.07, 1.81   0.01[a](#jdi12764-note-0006){ref-type="fn"}
  TZD/INS                                3             236/194                                   1.17                0.90, 1.51   0.24
  SGLT‐2i/INS                            8             820/718                                   1.09                0.96, 1.25   0.18
  GLP‐1RA/INS                            7             1,367/1,197                               1.24                0.99, 1.56   0.06
  Incidence of severe hypoglycemia (%)                                                                                            
  DPP‐4i/INS                             6             1,686/1,682                               0.94                0.45, 1.95   0.87
  AGI/INS                                2             154/154                                   1.00                0.14, 6.99   1.00
  SGLT‐2i/INS                            3             1,008/997                                 1.28                0.81, 2.03   0.28
  GLP‐1RA/INS                            7             1,393/1,223                               1.86                0.45, 7.57   0.39

*P*‐value \< 0.05. AGI, alpha‐glucosidase inhibitors; CI, confidence interval; DPP‐4i, dipeptidyl peptidase‐4 inhibitor; GLP‐1RA, glucagon‐like peptide‐1 receptor agonist; HbA1c, glycated hemoglobin; INS, insulin; MET, metformin; PBO, placebo; SGLT‐2i, sodium--glucose cotransporter 2 inhibitor; TZD, thiazolidinediones; WMD, weighted mean difference.

John Wiley & Sons, Ltd

Discussion {#jdi12764-sec-0022}
==========

In the present meta‐analysis, we found that treatment with DPP‐4 inhibitors in combination with insulin improved glycemic control without an increased risk of hypoglycemia and weight gain compared with a placebo in combination with insulin. When compared with AGI/INS, TZD/INS and GLP‐1RA/INS treatments, DPP‐4i/INS treatment had equivalent placebo‐corrected effects on HbA1c, FPG and PPG control.

DPP‐4 inhibitors prevent the degradation of the gastrointestinal incretins GLP‐1 and GIP[5](#jdi12764-bib-0005){ref-type="ref"}. With this insulin‐independent mode of action, the combination of DPP‐4 inhibitors and insulin showed superior glycemic control compared with insulin alone. It is recommended that patients begin insulin therapy when they cannot achieve glycemic control with oral antihyperglycemic agents alone[1](#jdi12764-bib-0001){ref-type="ref"}, [2](#jdi12764-bib-0002){ref-type="ref"}. These patients usually suffer from poorer islet cell function and have a higher risk of hypoglycemic episodes with insulin alone. The present meta‐analysis showed that the combined use of DPP‐4 inhibitors and insulin results in a significant decrease in daily insulin dosage, which further lowers the risk of hypoglycemia. The results regarding the efficacy and safety of DPP‐4i/INS treatment in our meta‐analysis were generally consistent with those from previous systematic reviews and meta‐analyses[6](#jdi12764-bib-0006){ref-type="ref"}, [7](#jdi12764-bib-0007){ref-type="ref"}, and we further updated the included studies. Taken together, the data supports that DPP‐4 inhibitors represent a good option as adjunctive agents to insulin therapy.

DPP‐4 inhibitors showed a level of hypoglycemic efficacy and safety equivalent to AGI or TZD when added to insulin therapy. This gives patients an alternate therapeutic option, especially those who cannot tolerate the side‐effects of metformin, AGI or TZD. In the comparison between the DPP‐4i/INS and MET/INS groups, MET/INS treatment showed a better placebo‐corrected effect in HbA1c control with less weight gain. However, the numbers of participants of these two groups differed greatly, which might limit the statistical power.

GLP‐1 receptor agonist, another incretin‐based therapy, had a significant HbA1c‐lowering effect in combination with insulin compared with PBO/INS.

In a previous meta‐analysis that included 89 RCTs, GLP‐1 receptor agonist had an effect on weight loss[45](#jdi12764-bib-0045){ref-type="ref"}. This effect was reproduced when GLP‐1 receptor agonists and DPP‐4 inhibitors were used with insulin therapy. The placebo‐corrected risk of hypoglycemia or severe hypoglycemia between DPP‐4i/INS and GLP‐1RA/INS treatments was not significantly different (*P* \> 0.05). Therefore, patients with a weight problem could consider using a GLP‐1 receptor agonist in combination with insulin for the weight loss effect.

SGLT‐2is induce urinary glucose excretion through inhibition of renal glucose reabsorption, improve glycemic control and reduce bodyweight[46](#jdi12764-bib-0046){ref-type="ref"}, [47](#jdi12764-bib-0047){ref-type="ref"}, [48](#jdi12764-bib-0048){ref-type="ref"}. Significant HbA1c‐ and PPG‐lowering effects were seen with SGLT‐2i/INS compared with PBO/INS. There was also significant weight reduction that was not accompanied by a higher risk of hypoglycemia or severe hypoglycemia in the present meta‐analysis.

In the comparison between the DPP‐4i/INS and the SGLT‐2i/INS groups, SGLT‐2i/INS treatment exerted a better placebo‐corrected effect in PPG control, with less weight gain and no higher risk of hypoglycemia. This result is generally consistent with a previous study[49](#jdi12764-bib-0049){ref-type="ref"}. However, in the systematic review and meta‐analysis by Min *et al*., the HbA1c reduction was significantly greater in the SGLT2i/INS group than in the DPP4i/INS group after adjusting for age, sex, BMI and baseline insulin dose^50^. Several previous studies have reported the weight‐neutral effect of DPP‐4 inhibitors and the weight reduction effect of SGLT‐2 inhibitors. Results from the present meta‐analysis suggested that these effects were preserved with the addition of insulin therapy. It is well known that obesity is associated with insulin resistance, and weight loss improves insulin resistance and glycemic control. Taken together, these results support that SGLT‐2i is a better option for glycemic control, especially for those patients with a higher BMI.

The present meta‐analysis systematically evaluated the efficacy and safety of DPP‐4i/INS treatment compared with a placebo or other antihyperglycemic agents in combination with insulin therapy. However, there are several potential limitations. First, the present meta‐analysis comprised studies with different baseline characteristics and therapeutic regimens, which might lead to bias of the results. Second, the numbers of participants in some treatment groups were different greatly, such as DPP‐4i/INS vs MET/INS treatment, which might limit the statistical power. Additionally, hypoglycemia and severe hypoglycemia were not clearly defined in several studies, leading to heterogeneity across studies. More studies with a larger sample size, longer duration of follow up and more head‐to‐head comparisons are required to substantiate the present results.

According to this meta‐analysis, treatment with DPP‐4 inhibitors combined with insulin improves glycemic control without increasing the risk of hypoglycemia and weight gain compared with insulin treatment alone. DPP‐4i/INS treatment was equally effective in placebo‐corrected glycemic control compared with AGI/INS, TZD/INS and GLP‐1RA/INS treatments.
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